Background: Drug-eluting stents (DES) have been shown to reduce the rate of acute
complications and the need for subsequent revascularization in cases where single-vessels are treated.
The performance of DES in patients with multivessel disease and complex lesions, however, remains
controversial. This study assessed and compared clinical outcomes following single vs. multivessel percutaneous coronary
intervention (PCI), using the Supraflex sirolimus-eluting stent (SES), in an all-comers patient population.
Methods: We conducted retrospective, multicenter, all-comers, observational study of 995 patients, who underwent either
single-vessel PCI (n=769 patients; group-I) or multivessel PCI (n=226 patients; group-II), treated with the biodegradable
polymer coated Supraflex SES, between July-2013 and May-2014 at nine different centers in India. Pre-specified primary
endpoint, rate of major adverse cardiac events (MACE) [defined as composite of cardiac death, myocardial infarction
(MI), target lesion revascularization (TLR) and non-target lesion target vessel revascularization (non-TL TVR)], was
analyzed during 12 months after the post-index procedure. We also analyzed the incidence of stent thrombosis (ST) as a
safety endpoint during the follow-up period, as defined by the Academic Research Consortium (ARC).
Results: Of the whole study group, 1,242 lesions were treated in 995 patients (mean age 61.6±10.8 years; 80.0% male)
with average stent length of 26.8±9.3 mm. Multivessel PCI patients were older, had a higher prevalence of arterial
hypertension, were smoker, had a family history of coronary artery disease, previous stroke and previous PCI compared to
single-vessel PCI patients. Follow-up was available in 99.0% (761/769) of patients with single-vessel intervention and
96.9% (219/226) of patients with multivessel intervention at the end of 12 months. In-hospital MACE was similar for both
the groups [group-I, 3 (0.4%) vs. group-II, 1 (0.4%); p=1.000]. The observed MACE for group-I and group-II, at 30 days,
6 and 12 months follow-up were 9 (1.2%) vs. 2 (0.9%); p=1.000, 15 (2.0%) vs. 7 (3.2%); p=0.302 and 24 (3.2%) vs. 12
(5.5%); p=0.109, respectively. The cumulative incidence curves for MACE showed no significant differences between the
two groups, at the end of 12 months (p=0.109).
Conclusion: Our study shows that use of the Supraflex SES in single and multivessel coronary artery disease produces
good clinical outcomes during 12 months of follow-up with a low rate of revascularization, despite complex lesion